Reduction of allogeneic transplant morbidity by combining peripheral blood and bone marrow progenitor cells.
One case has been reported of a patient undergoing allogeneic transplantation with peripheral blood progenitor cells (PBPCs) rather than bone marrow. We now report the first case of a patient who underwent an allogeneic transplant with bone marrow combined with PBPCs.
Nemunaitis
J
J
Western Pennsylvania Cancer Institute, West Penn Hospital, Department of Hematology/Oncology, Pittsburgh.
Albo
V
V
Zeigler
Z R
ZR
Shadduck
R K
RK
Rosenfeld
C S
CS
D000666:Amphotericin B / Q000627:therapeutic use; D001228:Aspergillosis / Q000150:complications / Q000188:drug therapy; D016913:Blood Component Transfusion; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000379:methods*; D002648:Child; D003115:Colony-Stimulating Factors / Q000627:therapeutic use; D003131:Combined Modality Therapy; D017809:Fatal Outcome; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008172:Lung Diseases, Fungal / Q000150:complications; D011994:Recombinant Proteins / Q000627:therapeutic use; D016879:Salvage Therapy; D014184:Transplantation, Homologous
D003115:Colony-Stimulating Factors; D007155:Immunologic Factors; D011994:Recombinant Proteins; D000666:Amphotericin B